ABSTRACT
Background Obstructive sleep apnea (OSA) and its features, such as chronic intermittent hypoxia (IH), may differentially affect specific molecular pathways and processes in the pathogenesis of coronary artery disease (CAD) and influence the subsequent risk and severity of CAD events. In particular, competing adverse (e.g. inflammatory) and protective (e.g. increased coronary collateral blood flow) mechanisms may operate, but remain poorly understood. We hypothesize that common genetic variation in selected molecular pathways influences the likelihood of CAD events differently in individuals with and without OSA, in a pathway-dependent manner.
Methods We selected a cross-sectional sample of 471,877 participants from the UK Biobank, among whom we ascertained 4,974 to have OSA, 25,988 to have CAD, and 711 to have both. We calculated pathway-specific polygenic risk scores (PS-PRS) for CAD, based on 6.6 million common variants evaluated in the CARDIoGRAMplusC4D genome-wide association study (GWAS), annotated to specific genes and pathways using functional genomics databases. Based on prior evidence of involvement with IH and CAD, we tested PS-PRS for the HIF-1, VEGF, NFκB and TNF signaling pathways.
Results In a multivariable-adjusted logistic generalized additive model, elevated PS-PRSs for the KEGG VEGF pathway (39 genes) associated with protection for CAD in OSA (interaction odds ratio 0.86, p = 6E-04). By contrast, the genome-wide CAD PRS did not show evidence of statistical interaction with OSA.
Conclusions We find evidence that pathway-specific genetic risk of CAD differs between individuals with and without OSA in a qualitatively pathway-dependent manner, consistent with the previously studied phenomena whereby features of OSA may have both positive and negative effects on CAD. These results provide evidence that gene-by-environment interaction influences CAD risk in certain pathways among people with OSA, an effect that is not well-captured by the genome-wide PRS. These results can be followed up to study how OSA interacts with genetic risk at the molecular level, and potentially to personalize OSA treatment and reduce CAD risk according to individual pathway-specific genetic risk profiles.
Competing Interest Statement
Dr. Goodman reports grants from National Heart, Lung, and Blood Institute, NIH, during the conduct of the study; Dr. Cade has nothing to disclose; Dr. Shah has nothing to disclose; Dr. Huang has nothing to disclose; Dr. Dashti has nothing to disclose; Dr. Saxena has nothing to disclose; Dr. Rutter reports consulting fees and non-promotional lecture fees from Novo Nordis, outside the submitted work; Dr. Libby was an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion, Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Merck, Novartis, Pfizer, Sanofi-Regeneron. Dr. Libby is a member of scientific advisory boards for Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, and XBiotech, Inc during the conduct of this study; Dr. Libby's laboratory has received research funding in the last two years from Novartis; Dr. Libby also reports grants from the National Heart, Lung, and Blood Institute, the American Heart Association, the RRM Charitable Fund, and the Simard Fund during the conduct of this study; Dr. Libby is on the Board of Directors of XBiotech, Inc. Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies; in addition, Dr. Libby has a patent Use of Canakinumab pending to Ridker P, Thuren T, Bermann G, Libby P, inventors; Dr. Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies; Dr. Sofer has nothing to disclose. Dr. Redline reports grants from NIH during the conduct of the study; grants and personal fees from Jazz Pharma, personal fees from Eisai Inc, personal fees from Apnimed Inc, outside the submitted work; and Dr. Redline is the first incumbent of an endowed professorship donated to the Harvard Medical School by Dr. Peter Farrell, the founder and Board Chairman of ResMed, through a charitable remainder trust instrument, with annual support equivalent to the endowment payout provided to the Harvard Medical School during Dr. Farrell's lifetime by the ResMed Company through an irrevocable gift agreement.
Funding Statement
Dr. Goodman reports grants from the National Heart, Lung, and Blood Institute, NIH; Dr. Rutter reports funding from The University of Manchester (Research Infrastructure Fund)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Investigating pathway-specific genetic risk of coronary artery disease and its relationship with intermittent hypoxia in obstructive sleep apnea IR Approved v1.0 PI: Goodman, Matthew (MG185) Sponsor: NIH-National Institutes of Health Agreement #: 2020A010894
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available on request from UK Biobank.